HALO
Halozyme Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$77.09-0.93%
Price as of Jul 20, 2026
HALO financials
Halozyme Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $1.4B | $1.0B | $829.3M | $660.1M |
| Cost of revenue | $305.4M | $159.4M | $192.4M | $139.3M |
| Gross profit | $1.1B | $855.9M | $636.9M | $520.8M |
| Operating expenses | $274.9M | $304.4M | $299.3M | $253.3M |
| Operating income | $816.3M | $551.5M | $337.6M | $267.5M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M |
| EBITDA | $573.1M | $656.5M | $451.9M | $315.5M |
| Basic EPS | $2.64 | $3.50 | $2.13 | $1.48 |
| Diluted EPS | $2.56 | $3.43 | $2.10 | $1.44 |
| Balance sheet | ||||
| Cash & equivalents | $133.8M | $115.8M | $118.4M | $234.2M |
| Total assets | $2.5B | $2.1B | $1.7B | $1.8B |
| Total liabilities | $2.5B | $1.7B | $1.6B | $1.7B |
| Stockholders’ equity | $48.8M | $363.8M | $83.8M | $169.8M |
| Total debt | $2.1B | $1.5B | $1.5B | $1.5B |
| Net debt | $2.0B | $1.4B | $1.4B | $1.3B |
| Cash flow | ||||
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M |
| Capital expenditure | -$7.0M | -$10.7M | -$15.3M | -$4.8M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$342.4M | -$250.0M | -$402.4M | -$200.0M |